^
    Back
    Association details:
    Biomarker:SETDB1 overexpression
    Cancer:Breast Cancer
    Drug:tamoxifen (Estrogen receptor antagonist)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    Breast Cancer Res
    Title:

    SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance

    Published date:
    04/08/2022
    Excerpt:
    As expected from previous studies, overexpression of SETDB1 significantly enhanced the colony formation ability, while PELP1-KD significantly attenuated the SETDB1 mediated increase in the clonogenicity of both MCF7 and ZR75 models (Fig. 5B). Further, SETDB1 overexpression models exhibited resistance to tamoxifen treatment...
    DOI:
    10.1186/s13058-022-01520-4
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    SABCS 2020
    Title:

    Proto-oncogene PELP1 interactions with SETDB1 contribute to aberrant activation of AKT1 in breast cancer

    Published date:
    11/17/2020
    Excerpt:
    Using two different shRNAs targeting SETDB1 and multiple BCa model cells, we provided evidence that SETDB1 plays an important role in the proliferation of BCa cells. SETDB1 upregulation is sufficient to accelerate proliferation and PELP1 knockdown attenuated SETDB1 oncogenic functions.SETDB1 overexpression contributed to resistance to tamoxifen treatment.